<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-WF45SNLA</identifier><date>2008</date><creator>Kravos, Matej</creator><creator>Malešič, Ivan</creator><relation>documents/znanstveni_clanki/farmacevtski_vestnik/html/urn_nbn_si_doc-wf45snla.html</relation><relation>documents/znanstveni_clanki/farmacevtski_vestnik/pdf/urn_nbn_si_doc-wf45snla.pdf</relation><relation>documents/znanstveni_clanki/farmacevtski_vestnik/txt/urn_nbn_si_doc-wf45snla.txt</relation><format format_type="issue">1</format><format format_type="volume">59</format><format format_type="main">7 strani</format><format format_type="type">article</format><format format_type="extent">str. 27-33</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID">239703808</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-WF45SNLA</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">antipsihotiki</subject><subject language_type_id="slv">duševne bolezni</subject><subject language_type_id="slv">hiperprolaktinemija</subject><title>Hiperolaktinemija pri antipsihotioeni terapiji</title><title>Hyperprolactinemia in antipsychotic therapy</title></Record>